| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2b topline data readout example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Cardiovascular System | ||
Phase 2b topline data readout example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Cardiovascular System | ||
Phase 2b topline data readout example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Cardiovascular System |
Recent Updates
Recently added Catalysts
Kardigan, Inc. Common Stock
$14.75
+0.09 (+0.61%)
Market Cap
1.38 B
EPS
-
P/E Ratio
-
Value Trade
5.60 M
1.58 %
Week
-26.84 %
1 Month
-38.82 %
3 Month
-32.95 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
487.83 K
52 Week Range
-
% held by Insiders
31.67 %
% held by Institutions
61.63 %
Enterprise Value
718.49 M
Total Shares
93.50 M
Short %
4.02 %
Float Shares
63.89 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kardigan, Inc. Common Stock
14Total events
6Upcoming
6Tier-1 (high impact)
2026 – 2027Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
●Oral PresentationPresentation
Subscribe to view catalyst details
TBD
◆Oral PresentationdanicamtivPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
INSIDER TRANSACTIONSMonthly totals, since 2023
BuysSellsStock price
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in KARD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
KARD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-KARD
Sep 30, 2026▲ +0.6%today
Kardigan Announces Appointment of Kristin Reinke to its Board of Directors
Kardigan has appointed Kristin Reinke to its Board of Directors, where she will take on the role of chair of the Audit Committee. This strategic move is aimed at enhancing the company's governance and oversight capabilities. Reinke's experience is expected to contribute positively to Kardigan's leadership.
Read more →-KARD
Sep 2, 2026▼ -5.4%on this news
Kardigan to Present at Two September Investor Conferences
Kardigan, based in South San Francisco and Princeton, will present at two significant investor conferences: the 2026 Cantor Global Healthcare Conference and Baird's 2026 Global Healthcare Conference. This participation aims to enhance the company's visibility and engage with potential investors.
Read more →-KARD
Aug 11, 2026Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
Kardigan, Inc. has announced its financial results for the second quarter of 2026, ending on June 30. Alongside the financial data, the company has shared recent updates regarding its business operations. The report reflects the company's ongoing activities and performance in the biopharma sector.
Read more →-KARD
Jun 22, 2026Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Kardigan has successfully completed its initial public offering (IPO), with the underwriters fully exercising their option to purchase additional shares. This development reflects a positive outlook and strong demand from investors. The IPO is expected to enhance Kardigan's financial position and growth potential.
Read more →-KARD
Jun 18, 2026Kardigan Announces Pricing of Upsized Initial Public Offering
Kardigan, Inc. has announced the pricing of its initial public offering (IPO) of 25 million shares at $16 each, aiming to raise $400 million. The shares will begin trading on the Nasdaq under the ticker 'KARD' on June 18, 2026, with the offering expected to close on June 22, 2026. Kardigan focuses on developing precision therapeutics for cardiovascular diseases lacking approved treatments.
Read more →-KARD
Mar 28, 2026Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC
Kardigan announced positive results from its Phase 2 trial of tonlamarsen for uncontrolled hypertension. The drug showed significant reductions in plasma angiotensinogen and systolic blood pressure. These findings support the launch of a Phase 2b trial targeting acute severe hypertension. Tonlamarsen was well-tolerated with a favorable safety profile.
Read more →-KARD
Mar 17, 2026Kardigan Announces Multiple Presentations at ACC.26 from its Late-Stage Portfolio of Personalized Cardiovascular Medicines
Kardigan will present multiple studies at the ACC.26, including late-breaking Phase 2 data on tonlamarsen for uncontrolled hypertension. Prolaio, a subsidiary, will showcase research on continuous monitoring and novel biomarkers in cardiovascular care. These presentations highlight Kardigan's commitment to advancing cardiovascular therapeutics and improving patient outcomes.
Read more →-KARD
Jan 6, 2026Kardigan Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference and Provides Corporate Update for 2026
Kardigan has announced its participation in the 44th Annual J.P. Morgan Healthcare Conference and provided a corporate update for 2026. The company is poised for significant advancements in cardiovascular drug development, with multiple clinical data readouts expected across its late-stage programs. Additionally, Andy Pasternak has been appointed as chief strategy officer, enhancing the leadership team as Kardigan aims to address unmet needs in cardiovascular care.
Read more →-KARD
Nov 7, 2025Kardigan Presents Positive Phase 2 Data on Ataciguat in Patients with Moderate Calcific Aortic Valve Stenosis at American Heart Association Scientific Sessions 2025
Kardigan presented positive Phase 2 data on ataciguat for patients with moderate calcific aortic valve stenosis at the American Heart Association Scientific Sessions 2025. The results indicated that ataciguat reduced aortic valve calcium and improved cardiac function compared to placebo. The findings suggest a potential shift from watchful waiting to a disease-modifying treatment for this condition.
Read more →-KARD
Oct 14, 2025Kardigan Raises $254 Million Series B to Advance Late-Stage Portfolio of Personalized Cardiovascular Medicines
Kardigan has successfully raised $254 million in Series B financing to advance its late-stage portfolio targeting specific types of dilated cardiomyopathy, acute severe hypertension, and calcific aortic valve stenosis. The funding will facilitate multiple data readouts starting in 2026. Kardigan aims to redefine cardiovascular disease treatment by addressing root causes rather than just managing symptoms.
Read more →-KARD
Sep 29, 2025Kardigan Announces Presentation of Positive Phase 2a Data for Danicamtiv in Patients with Dilated Cardiomyopathy at HFSA Annual Scientific Meeting 2025
Kardigan announced positive Phase 2a data for danicamtiv in patients with genetic dilated cardiomyopathy (DCM) at the HFSA Annual Scientific Meeting 2025. The results demonstrated significant improvements in left ventricular ejection fraction and left atrial function index. Danicamtiv was well tolerated, with no drug-related adverse events leading to discontinuation. The findings support ongoing development and future trials.
Read more →Competitive Position
How KARD ranks across every disease it competes inCompetitive Position is a premium feature
See how KARD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial